

ASX RELEASE

12 August 2024

AMPLIA RECEIVES R&D TAX REBATE TOTALLING \$ 3.2 MILLION

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to advise that it has received a Research and Development (R&D) Tax Incentive refund of \$3,177,718 for the 2023/2024 financial year. The refund relates to expenditure incurred in research and development associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886.

These R&D activities primarily related to the Company’s ongoing Phase 1b/2a clinical trial of narmafotinib in advanced pancreatic cancer patients.

Following receipt of the funds, the Company will fully repay the loan of \$1,467,000 received from Director Dr Robert Peach along with accrued interest¹. The net funds will contribute to the further progression of the Company’s Phase 1b/2a clinical trial of narmafotinib and other R&D activities.

The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities.

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), [Threads](https://www.threads.net/@ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).

¹ Quarterly Activities And Cash Flow Reports 30 January 2024